President Macron is relocalising: reshoring the production of pharmaceuticals
Several references have been made on this site about the growing awareness of the need to develop strong British supply chains which will reduce the high carbon dioxide emissions caused by transporting goods made in other countries.
Reshoring (aka onshoring, inshoring, or backshoring) is the process of returning the production and manufacturing of goods back to the company’s original country.
It is the opposite of offshoring, the process of manufacturing goods overseas to try to reduce the cost of labour and manufacturing. Some readers may enjoy reading about the downside of offshoring, described in detail by Bryan Luoma.
Twenty two leading industrial engineering associations in the Reshoring UK initiative, aim to connect manufacturers with trusted suppliers capable of delivering UK-based products and services.
The reshoring trend has been explored and publicised by Professor David Bailey since 2013; he reported in the Birmingham Post (archived to Birmingham Live) that “repatriating activity – including some sourcing – to the UK is very much on the agenda”. In 2018, Bailey and Lisa De Propris suggested that the advantages include the skilled jobs created which have a multiplier effect, stimulating demand and – in turn – leading to additional employment opportunities.
Many journalists and NGOs have focussed on food security and the Farmers Weekly reports the incorporation of three measures to encourage this in the Agriculture Bill
https://www.nfuonline.com/news/latest-news/expert-insight-the-agriculture-bill-2020/
Today the French President, Emmanuel Macron, adds another important advantage – that of security
The Covid-19 pandemic has alerted the French president to the need for France to invest in reshoring, to produce more medical equipment and pharmaceuticals within its borders and to finance a ’much-needed’ initiative to repatriate the production of critical medicines.
Critics said the pandemic exposed the weakness of France’s healthcare system after masks, tests and drugs ran short, leaving it with far more deaths than neighbouring Germany. “Everyone saw during this crisis that certain drugs were no longer manufactured in France or even in Europe”.
Mr Macron said in a speech at Sanofi. “We must draw lessons from that. . . and the state is ready to invest in such reshoring projects.”
Macron unveils a much-needed initiative to bring home production of critical medicines during a visit to Sanofi, a French pharmaceutical MNC
in June France issued a call for companies to indicate interest in bringing back production of 30 generic drugs used to fight Covid-19, including medicines used for patients on ventilators, painkillers such as fentanyl and morphine and antibiotics.
Production will start with the country’s top-selling medicine, paracetamol – though Big Pharma opposes this, pointing out that it can be produced more cheaply in Asia. Mr Macron said that France is aiming to reshore production within three years.
.